Ziprasidone: a new atypical antipsychotic

Bibliography

• BALDESSARINI RJ: Chemotherapy in Psychiatry Harvard University Press, Cambridge, MA (1984):14–92.
   Google Scholar
• KECK PE, Jr., MCELROY SL: The new antipsychotics and their therapeutic potential. Psychiatry Ann. (1997) 27:320–331.
   Google Scholar
• KANE JM: Treatment of schizophrenia. Schizophr: Bull. (1987) 13:133–156.
   PubMed Web of Science ®Google Scholar
• CARPENTER WT: The deficit syndrome. Am. J. Psychiatry (1994) 157:327–329.
   Google Scholar
• CASEY DE: What makes a neuroleptic atypical? In: No Antipsychotic Drugs. Meltzer HY (Ed.) Raven Press, New York, NY (1992):241–251.
   Google Scholar
• KANE J, HONIGFELD G, SINGER J etal.: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch. Gen. Psychiatry (1988) 45:789–796.
   Google Scholar
• KECK PE, Jr., MCELROY SL, STRAKOWSKI SM et al.: Pharmacologic treatment of schizoaffective disorder. Psychopharmacology (1994) 114:529–538.
   PubMedGoogle Scholar
• GOLDSTEIN J: The new generation of antipsychotics: how atypical are they? Int. Neuropsychopharmacol (2000) 3:339–349.
   Google Scholar
• SEEGER TF, SEYMOUR PA, SCHMIDT PA et al.: Ziprasidone (CP 88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity Pharmacol Exp. Ther. (1995) 275:101–113.
   Google Scholar
• KO G, GOFF D, HERTZ L et al.: Status report: ziprasidone. Sdrizophr: Res. (1995) 15:154.
   Google Scholar
• TANDON R, HARRIGAN E, ZORN SH: Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. ..J. Semtunin Res. (1997) 4:159–177.
   Google Scholar
• MELTZER HY: Role of serotonin in the action of atypical antipsychotic drugs. Cl/n. Neuracci (1995) 3:64–75.
   Google Scholar
• KECK PE, JR, MCELROY SL, STRAKOWSKI SM: Schizoaffective disorder - Role of atypical antipsychotics. Schizophr Res. (1999) 35 (Suppl.):5–12.
   Google Scholar
• BENCH CJ, LAMMERTSMA AA, DOLAN RJ etal.: Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic (CP-88p59-01): a study using positron emission tomography and 11C-raclopride. Pkychopharmacol ogy (1993) 112:308–314.
   Google Scholar
• FISCHMAN A, BONAB AA, BABICH JW etal.: Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. Marmara Exp. Ther. (1996) 279:939–947.
   Google Scholar
• HESSELINK JMK, SAMBUNARIS A: Behavioral pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. Int. Rev Psych. (1995) 7:41–53.
   Google Scholar
• ROLLEMA H, LU Y, SCHMIDT AW etal.: 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Bid Psychiatry (2000) 48:229–237.
   Google Scholar
• HERTEL P, NOMIKOS CG, IURLO M et al.: Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (1996) 124:74–86.
   PubMed Web of Science ®Google Scholar
• KUROKI T, MELTZER HY, ICHIKAWA J: Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. j Pharmacol Exp. Ther. (1999) 288:774–781.
   PubMed Web of Science ®Google Scholar
• MOGHADDAM B, BUNNEY BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from the prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study J. Neurochem. (1990) 54:1755–1760.
   PubMed Web of Science ®Google Scholar
• WEINBERGER DR, LIPSKA BK: Cortical maldevelopment, antipsychotic drugs and schizophrenia Schizophr Res. (1995) 16:87–110.
   Google Scholar
• FLETCHER A, BILL DJ, CLIFFE EA etal.: A pharmacological profile of WAY-100635, a potent and selective 5-HT 1 A receptor antagonist. Br. J. Pharmacol (1994) 112:91.
   Google Scholar
• SPROUSE JS, REYNOLDS LS, BRASELTON JP et al.: Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of doral raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology (1999) 21:622–631.
   PubMed Web of Science ®Google Scholar
• BRILEY M, MORET C: Neurobiological mechanisms involved in antidepressant therapies. Clin. Neuropharmacol (1993) 16:387–400.
   PubMed Web of Science ®Google Scholar
• SHARMA RE SHAPIRO LE: The 5-HT1A receptor system: possible implications for schizophrenic negative symptoms. Psychiatric Ann. (1996) 26:88–92.
   Google Scholar
• TANDON R, BERTI C: Therapeutic benefits of ziprasidone: an update of clinical trials experience. Advances in Preclirilcal and Clinical Psychiatry (2000) 2:1–18.
   Google Scholar
• MICELI J, HUNT T, COLE MJ etal.: The pharmacokinetics (PK) of CP-88, 059 (CP) in healthy male volunteers following oral (P0) and intravenous (IV) administration. Clin. Pharmacol .Ther: (1994) 55:142.
   Google Scholar
• AWEEKAF, JAYESEKARAD, HORTON M etat The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. BE j Clin. Pharmacol (2000) 49:275–335.
   Google Scholar
• MICELI JJ, WILNER KD, HANSEN RA et al.: Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Brj Clin. Pharmacol (2000) 49:5–15.
   PubMed Web of Science ®Google Scholar
• PRAKASH C, KAMEL A, GUMMERUSJ et al.: Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. (1997) 25:863–872.
   PubMed Web of Science ®Google Scholar
• EVERSON G, LASSETER KC, ANDERSON KE etal.: The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Brj Clin. Pharmacol (2000) 49:21–26.
   Google Scholar
• PRAKASH C, KAMEL A, CUI D etal.: Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. BE j. Clin. Pharmacol (2000) 49:35–42.
   Google Scholar
• WILNER KD, TENSFELDT TG, BARIS B etal.: Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br j. Clin. Pharmacol (2000) 49:15–20.
   Google Scholar
• MUIRHEAD GJ, HARNESS J, HOLT PR et al.: Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br j. Clin. Pharmacol (2000) 49:49–56.
   PubMedGoogle Scholar
• WILNER KD, DEMATTOS DB, ANZIANO RJ etal.: Ziprasidone and the cytochrome P450 2D6 in healthy extensive metabolisers. Br j. Clin. Pharmacol (2000) 49:43–47.
   Google Scholar
• LAURENT A, MICELI JJ: The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers. BE j. Clin. Pharmacol (2000) 49:71–76.
   Google Scholar
• LAURENT A, WILNER KD: The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. BE j Clin. Pharmacol (2000) 49:65–70.
   Google Scholar
• APSELOFF G, WILNER KD, ANZIANO RJ etal.: The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br. J. Clin. Pharmcol (2000) 49:61–64.
   Google Scholar
• MICELI JJ, WILNER KD, TENSFELDT TG: Pharmacokinetics of intramuscular ziprasidone in healthy volunteers: results from two controlled studies. In: Abstracts of the American College of Neuropsychopharmacology Annual Meeting. San Juan, PR (December 13, 2000).
   Google Scholar
• GOFF DC, POSEVER T, HERZ L et al.: An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. j. Clin. Psychopharmacol (1998) 18:296–304.
   PubMed Web of Science ®Google Scholar
• KECK PE, Jr., BUFFENSTIEN A, FERGUSON J etal.: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (1998) 140:173–184.
   Google Scholar
• DANIEL DG, ZIMBROFF DL, POTKIN SG etal.: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmcology (1999) 20:491–505.
   Google Scholar
• KECK PE, Jr., REEVES KR, HARRIGAN EP etal.: Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. j. Clin. Psychopharmacol (2001) 21:27–35.
   Google Scholar
• KECK PE, Jr., ICE KN AND THE ZIPRASIDONE STUDY GROUP: Controlled treatment of acute mania with ziprasidone. In: Abstracts of the Annual Meeting of the American Psychiatric AssocMtion. Chicago, IL (May 13–18, 2000).
   Google Scholar
• SALLEE FR, KURLAN R, GOETZ CG et aL: Ziprasidone treatment of children and adolescents with Tourette's Syndrome: a pilot study. J. Am. Soc. Child Adolsc Psychiatry (2(X30) 39:292–299.
   Google Scholar
• LESEM MD, ZAJECKA JM, SWIFT RH et at.: Intramuscular ziprasidone, 2 mg versus 10 mg in the short-term management of agitated psychotic patients. j. OM. Psychiatry (2001) 62:12–18.
   Google Scholar
• REEVES KR, SWIFT RH, HARRIGAN EP etal.: A comparison of rapid-acting, intramuscular (IM) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation. Eur: Psychiatry (1998) 13(Suppl.):303–304.
   Google Scholar
• MELTZER HY, O'CONNOR R: Long-term efficacy of oral ziprasidone in schizophrenia: results of three controlled trials. In: Abstracts of the Annual Meeting of the American College of Neuropsychopharmacology San Juan, PR (December 13, 2000).
   Google Scholar
• ROMANO SJ: Cardiovascular safety profile of ziprasidone: review of clinical development data. In: Abstracts of the Annual Meeting of the American College of Neuropsychopharmacology San Juan, PR (December 13, 2000).
   Google Scholar
• Study 504. Pfizer, Inc. Study report of ziprasidone clinical pharmacology protocol. Rockville, MD: FDA Center for Drug Evaluation and Research Division of Cardiorenal Drug Products Consultation; June 14, 2000.
   Google Scholar
• FRYBURG DA, O'SULLIVAN RL, SIU C et aL: Insulin resistance in olanzapine- and ziprasidone-treated patients: interim results of a double-blind controlled 6-week trial. In: Abstracts of the Annual Meeting of the American College of Neuropsychopharmacology San Juan, PR (December 13, 2000).
   Google Scholar